top of page
News, Events and Updates
Search
Anavex Presents New Data on Preclinical Development of ANAVEX 3-71
Mar 13, 2016
AF710B, a Concomitant Activator of M1 Muscarinic and Sigma-1 Receptors: Possibly Disease-Modifying
Mar 13, 2016
Anavex Announces 2-Year Clinical Extension Study of ANAVEX 2-73 and Presents Phase 2a Dose-Response
Mar 10, 2016
Assessment of ANAVEX 2-73 in a MECP2 Rett Syndrome Mouse Model
Feb 26, 2016
Anavex Presents Precinical Results of ANAVEX 2-73 in Rett Syndrome
Feb 25, 2016
ANAVEX 2-73 Preclinical Data in New Indication to be Presented at ACTRIMS 2016
Feb 17, 2016
Sigma-1 Receptor Agonists Inhibit Oligodendrocyte Cytotoxicity Induced by Molecules
Feb 11, 2016
Anavex Reports Fiscal First Quarter 2016 Financial Results
Feb 8, 2016
Anavex to Present at 18th Annual BIO CEO & Investor Conference on February 9th 2016
Feb 2, 2016
14th International Athens / Springfield Symposium on Advances in Alzheimer Therapy
Feb 1, 2016
2016 Epilepsy Pipeline Conference
Jan 15, 2016
30
31
32
33
34
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
